Year: 2021
Type: review
Abstract: Functional neurological disorder (FND) was of great interest to early clinical neuroscience leaders. During the 20th century, neurology and psychiatry grew apart - leaving FND a borderland condition. Fortunately, a renaissance has occurred in the last two decades, fostered by increased recognition that FND is prevalent and diagnosed using "rule-in" examination signs. The parallel use of scientific tools to bridge brain structure - function relationships has helped refine an integrated biopsychosocial framework through which to conceptualize FND. In particular, a growing number of quality neuroimaging studies using a variety of methodologies have shed light on the emerging pathophysiology of FND. This renewed scientific interest has occurred in parallel with enhanced interdisciplinary collaborations, as illustrated by new care models combining psychological and physical therapies and the creation of a new multidisciplinary FND society supporting knowledge dissemination in the field. Within this context, this article summarizes the output of the first International FND Neuroimaging Workgroup meeting, held virtually, on June 17th, 2020 to appraise the state of neuroimaging research in the field and to catalyze large-scale collaborations. We first briefly summarize neural circuit models of FND, and then detail the research approaches used to date in FND within core content areas: cohort characterization; control group considerations; task-based functional neuroimaging; resting-state networks; structural neuroimaging; biomarkers of symptom severity and risk of illness; and predictors of treatment response and prognosis. Lastly, we outline a neuroimaging-focused research agenda to elucidate the pathophysiology of FND and aid the development of novel biologically and psychologically-informed treatments.
Source: NeuroImage Clinical
Authors: David L. Perez, Timothy R. Nicholson, Ali A. Asadi-Pooya, Indrit Bègue, Matthew Butler, Alan J. Carson, Anthony S. David, Quinton Deeley, Ibai Diez, Mark J. Edwards, Alberto J. Espay, Jeannette M. Gelauff, Mark Hallett, Silvina G. Horovitz, Johannes Jungilligens, Richard A.A. Kanaan, Marina A.J. Tijssen, Kasia Kozlowska, Kathrin LaFaver, W. Curt LaFrance, Sarah C. Lidstone, Ramesh S. Marapin, Carine W. Maurer, Mandana Modirrousta, Antje A.T.S. Reinders, Petr Sojka, Jeffrey P. Staab, Jon Stone, Jerzy P. Szaflarski, Selma Aybek
Institutions: Harvard University, Massachusetts General Hospital, King's College London, Thomas Jefferson University, Shiraz University of Medical Sciences, University of Geneva, University of Edinburgh, University College London, South London and Maudsley NHS Foundation Trust, St George's, University of London, University of Cincinnati, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, National Institutes of Health, National Institute of Neurological Disorders and Stroke, Universitätsklinikum Knappschaftskrankenhaus Bochum, Ruhr University Bochum, The University of Melbourne, Austin Health, University Medical Center Groningen, University of Groningen, The University of Sydney, Children's Hospital at Westmead, Westmead Institute for Medical Research, Northwestern University, Brown University, Rhode Island Hospital, University Health Network, University of Toronto, Stony Brook University, University of Manitoba, University Hospital Brno, Mayo Clinic, University of Alabama at Birmingham, University of Bern, University Hospital of Bern
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,150
Funders: National Science Foundation, U.S. Department of Defense, Parkinson's Disease Foundation, Spectrum Health Foundation, American Epilepsy Society, Sidney R. Baer, Jr. Foundation, Epilepsy Foundation, American Academy of Neurology, Biogen, Brown University, Oregon Health and Science University, Harvard Medical School, Emory University, Cleveland Clinic, International Parkinson and Movement Disorder Society, King’s College London, South London and Maudsley NHS Foundation Trust, Sunovion, Parkinson's Foundation, ACADIA Pharmaceuticals, Rhode Island Hospital, Ayers Foundation, National Institute for Health and Care Research, King's College London, National Research Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Eisai, Hôpitaux Universitaires de Genève, Université de Genève, H. Lundbeck A/S, National Institutes of Health, Allergan, University of Colorado Denver, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, UCB Pharma, U.S. Army Medical Research Acquisition Activity
Awards: G105322364, G2040153736, Treatments for Psychogenic Nonepileptic Seizures (NES), G4119534169, Neuroimaging Biomarkers of Symptom Severity, Adverse Life Events and Prognosis in Motor Functional Neurological Disorders, G5850682332, G7354288490, G8166743225, NEUROIMAGING BIOMARKER FOR SEIZURES, G8432398230
OpenAlex ID: W3135528090